NCT06443944 2026-03-06An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGCG Oncology, Inc.Available
NCT06111235 2026-01-12A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTCG Oncology, Inc.Phase 3 Active not recruiting367 enrolled